Sumitomo Pharma

4506.TPharmaceutical
Financials · Consolidated

From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 14
PeriodFormFiledFigures
2025-04-01 → 2026-03-31Annual2026-06-23190 figures · EDINET
2025-04-01 → 2025-09-30Half-year2025-11-0477 figures · EDINET
2024-04-01 → 2025-03-31Annual2025-06-26191 figures · EDINET
2024-04-01 → 2024-09-30Half-year2024-11-0177 figures · EDINET
2023-04-01 → 2024-03-31AnnualAmended2024-07-03192 figures · EDINET
2023-04-01 → 2024-03-31Annual2024-06-25192 figures · EDINET
2023-04-01 → 2023-12-31Quarterly Q32024-02-0199 figures · EDINET
2023-04-01 → 2023-09-30Quarterly Q22023-11-0299 figures · EDINET
2023-04-01 → 2023-06-30Quarterly Q12023-08-0377 figures · EDINET
2022-04-01 → 2023-03-31Annual2023-06-27194 figures · EDINET
2022-04-01 → 2022-12-31Quarterly Q32023-02-0299 figures · EDINET
2022-04-01 → 2022-09-30Quarterly Q22022-11-0299 figures · EDINET
2022-04-01 → 2022-06-30Quarterly Q12022-08-0377 figures · EDINET
2021-04-01 → 2022-03-31Annual2022-06-23209 figures · EDINET

21 more reports are still being processed.

Segments · FY ended 2026-03
SegmentExternal salesProfit
Asia¥23.0bn¥9.5bn
Japan¥92.4bn¥12.4bn
North America¥337.9bn¥75.7bn
Total¥453.3bn¥97.5bn

Segment names from EDINET member IDs; not mapped to a common taxonomy.